osimertinib + sintilimab

Osimertinib + sintilimab is an investigational combination therapy for cancer treatment. Osimertinib is a third-generation small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively targets both EGFR-sensitizing mutations and the T790M resistance mutation in non-small cell lung cancer (NSCLC). Sintilimab is a monoclonal antibody that acts as an immune checkpoint inhibitor by targeting programmed cell death protein 1 (PD-1), thereby enhancing anti-tumor immune responses. This combination aims to address acquired resistance to EGFR-TKIs in patients with EGFR-mutant NSCLC by combining targeted inhibition of tumor growth signaling with immunotherapy-mediated enhancement of anti-tumor immunity. The combination has been explored primarily in clinical trials for patients who have progressed after prior EGFR-TKI therapy[3][6].

Other names

osimertinib + sintilimab